Treatment of Neurological Autoimmune Diseases with Immunoglobulins: First Insights from the Prospective SIGNS Registry

[1]  W. Kirch,et al.  Immunoglobulins for primary or secondary immunodeficiency or for immunomodulation in neurological autoimmune diseases: insights from the prospective SIGNS registry , 2012, Journal of Public Health.

[2]  R. Gold,et al.  [Administration of intravenous immunoglobulins in neurology. An evidence-based consensus: update 2010]. , 2011, Der Nervenarzt.

[3]  A. Bowling.  COMPLEMENTARY AND ALTERNATIVE MEDICINE IN MULTIPLE SCLEROSIS , 2010, Continuum.

[4]  W. Kirch,et al.  [Assessment of immunoglobulins in a long-term non-interventional study (SIGNS Study). Rationale, design, and methods]. , 2010, Medizinische Klinik.

[5]  W. Kirch,et al.  Prospektive Versorgungsforschungsstudie zur Therapie mit Immunglobulinen (SIGNS) , 2010, Medizinische Klinik.

[6]  R. Hughes,et al.  Confirming the efficacy of intravenous immunoglobulin in CIDP through minimum clinically important differences: shifting from statistical significance to clinical relevance , 2010, Journal of Neurology, Neurosurgery & Psychiatry.

[7]  R. Gold,et al.  Einsatz intravenöser Immunglobuline in der Neurologie , 2010, Der Nervenarzt.

[8]  L. H. van den Berg,et al.  Intravenous Immunoglobulin Treatment in Multifocal Motor Neuropathy , 2010, Journal of Clinical Immunology.

[9]  S. Jacob,et al.  Current Proposed Mechanisms of Action of Intravenous Immunoglobulins in Inflammatory Neuropathies , 2009, Current neuropharmacology.

[10]  R. Hughes.  Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy: the ICE trial , 2009, Expert review of neurotherapeutics.

[11]  J. Jakobsen,et al.  Subcutaneous versus intravenous immunoglobulin in multifocal motor neuropathy: a randomized, single‐blinded cross‐over trial , 2009, European journal of neurology.

[12]  H. Hartung,et al.  Health-related quality-of-life improvements in CIDP with immune globulin IV 10% , 2009, Neurology.

[13]  S. Piepers,et al.  New liquid intravenous immunoglobulin (10 % IVIg) for treatment of multifocal motor neuropathy , 2008, Journal of Neurology.

[14]  M. Stangel.  Review: New advances in the treatment of neurological diseases using high dose intravenous immunoglobulins , 2008, Therapeutic advances in neurological disorders.

[15]  N. Gilhus,et al.  EFNS guidelines for the use of intravenous immunoglobulin in treatment of neurological diseases , 2008, European journal of neurology.

[16]  H. Hartung,et al.  Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial , 2008, The Lancet Neurology.

[17]  E. Brähler,et al.  Die Version 2.0 des SF-36 Health Survey - Ergebnisse einer bevölkerungsrepräsentativen Studie , 2005, Sozial- und Präventivmedizin.

[18]  W. Greiner,et al.  Validating the EQ-5D with time trade off for the German population , 2005, The European Journal of Health Economics.

[19]  V. Exner.  Fragebogen zur Lebenszufriedenheit (FLZ). , 2001 .

[20]  B. Bellach,et al.  Der SF-36 im Bundes-Gesundheitssurvey Erste Ergebnisse und neue Fragen , 2000, Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz.

[21]  E. Gabor.  Intravenous immune globulin. , 1995, The Western journal of medicine.

[22]  C. Sherbourne,et al.  The MOS 36-Item Short-Form Health Survey (SF-36) , 1992 .

[23]  R. Gold,et al.  Drug Insight: the use of intravenous immunoglobulin in neurology—therapeutic considerations and practical issues , 2007, Nature Clinical Practice Neurology.

[24]  M. Bullinger,et al.  [The version 2.0 of the SF-36 Health Survey: results of a population-representative study]. , 2005, Sozial- und Praventivmedizin.

[25]  Ware J.E.Jr.,et al.  THE MOS 36- ITEM SHORT FORM HEALTH SURVEY (SF- 36) CONCEPTUAL FRAMEWORK AND ITEM SELECTION , 1992 .

[26]  Lissa Shudak,et al.  Intravenous immune globulin. , 1992, The Medical letter on drugs and therapeutics.